CN112237287B - 一株能够缓解便秘的鼠李糖乳杆菌lr519及其组合物 - Google Patents
一株能够缓解便秘的鼠李糖乳杆菌lr519及其组合物 Download PDFInfo
- Publication number
- CN112237287B CN112237287B CN202011343439.6A CN202011343439A CN112237287B CN 112237287 B CN112237287 B CN 112237287B CN 202011343439 A CN202011343439 A CN 202011343439A CN 112237287 B CN112237287 B CN 112237287B
- Authority
- CN
- China
- Prior art keywords
- powder
- lactobacillus rhamnosus
- parts
- constipation
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010010774 Constipation Diseases 0.000 title claims abstract description 53
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 239000000843 powder Substances 0.000 claims abstract description 70
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 29
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 26
- 241000894006 Bacteria Species 0.000 claims abstract description 24
- 230000001580 bacterial effect Effects 0.000 claims description 16
- 229920001202 Inulin Polymers 0.000 claims description 15
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 15
- 229940029339 inulin Drugs 0.000 claims description 15
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 13
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 13
- 244000134552 Plantago ovata Species 0.000 claims description 12
- 235000003421 Plantago ovata Nutrition 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 10
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- 239000010903 husk Substances 0.000 claims description 8
- 239000006041 probiotic Substances 0.000 abstract description 20
- 235000018291 probiotics Nutrition 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 17
- 230000013872 defecation Effects 0.000 description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 14
- 230000000529 probiotic effect Effects 0.000 description 11
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 10
- 241000607598 Vibrio Species 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 7
- 229930003268 Vitamin C Natural products 0.000 description 7
- 235000019154 vitamin C Nutrition 0.000 description 7
- 239000011718 vitamin C Substances 0.000 description 7
- 210000003608 fece Anatomy 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000233866 Fungi Species 0.000 description 5
- 235000013325 dietary fiber Nutrition 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000006477 desulfuration reaction Methods 0.000 description 4
- 230000023556 desulfurization Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000014617 hemorrhoid Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 239000009223 Psyllium Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000002052 colonoscopy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 229940070687 psyllium Drugs 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010048946 Anal abscess Diseases 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000178557 Corallium Species 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 229920002670 Fructan Polymers 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000036581 Haemorrhagic anaemia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- UTDFQMAXCUGNJR-UHFFFAOYSA-N aucubin Natural products OCC1OC(Oc2ccoc2C3C(O)CCC3O)C(O)C(O)C1O UTDFQMAXCUGNJR-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000011615 dehydroascorbic acid Substances 0.000 description 1
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000004840 megacolon Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- LHFJOBMTAJJOTB-JLAZNSOCSA-N monodehydro-L-ascorbic acid Chemical compound [O]C1=C(O)C(=O)O[C@@H]1[C@@H](O)CO LHFJOBMTAJJOTB-JLAZNSOCSA-N 0.000 description 1
- 239000011744 monodehydroascorbic acid Substances 0.000 description 1
- 235000007352 monodehydroascorbic acid Nutrition 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于益生菌技术领域,提出了一株能够缓解便秘的鼠李糖乳杆菌LR519及其组合物,所述组合物包括质量比为1:(1‑2)的鼠李糖乳杆菌LR519菌粉与两歧双歧杆菌TMC3115菌粉。通过上述技术方案,解决了现有技术中益生菌缓解便秘效果依旧不够好的问题。
Description
技术领域
本发明属于益生菌技术领域,涉及一株能够缓解便秘的鼠李糖乳杆菌LR519及其组合物。
背景技术
便秘(constipation),主要是指排便频率减少,一周内大便次数少于2-3次,或者2-3天才大便1次,粪便量少且干结时称为便秘。由于便秘是一种较为普遍的症状,症状轻重不一,所以一般不会引起人们的注意,大部分人并不把便秘当成疾病来对待,因而也就忽视了便秘的危害,其实便秘的危害很大,便秘的局部影响就是粪便干硬,排便时可能会引起肛裂,肛周脓肿、出血,出现失血性贫血等全身症狀;粪便长时间储存于肠道内,其中未完全消化的蛋白质、脂肪等物质,在肠道这种厌氧的环境下,发酵产生酚、胺等22种毒素,从而被肠道反复吸收,导致皮肤粗糙、痤疮、面部皱纹、肥胖、失眠及内分泌失调,让美丽的青春暗淡无光,美丽的容颜悄悄逃走;便秘可导致患者出现食欲不振、腹部胀满口苦、肛门排气多等表现;便秘也会诱发心绞痛,心肌梗死,脑出血,颅内压增高等,中老年人特别是患有高血压、心脏病人群,便秘则会诱发心肌梗塞,甚至猝死。脱硫弧菌和绿脓杆菌是重要的内毒素产生菌,其丰度与便秘状态的发生高度相关。益生菌因其具有突出的优势被人们广泛用于调节肠道,缓解便秘,但是现有的益生菌仍存在缓解便秘效果依旧不够好。
发明内容
本发明提出一株能够缓解便秘的鼠李糖乳杆菌LR519及其组合物,解决了现有技术中益生菌缓解便秘效果依旧不够好的问题。
本发明的技术方案是这样实现的:一种能够缓解便秘的鼠李糖乳杆菌LR519组合物,所述组合物包括质量比为1:(1-2)的鼠李糖乳杆菌LR519菌粉与两歧双歧杆菌TMC3115菌粉。
进一步地,所述组合物包括质量比为1:(1-2)的鼠李糖乳杆菌LR519菌粉与两歧双歧杆菌TMC3115菌粉。
上述能够缓解便秘的鼠李糖乳杆菌LR519组合物的应用,用于制备缓解便秘的食品。
进一步地,按质量份数计,所述食品包括3-5份混合菌粉A,30-50份圆苞车前子壳,20-30份低聚果糖,4-10份菊粉,4-6份柳橙果粉;
所述混合菌粉A包括质量比为1:(1-2)的鼠李糖乳杆菌LR519菌粉与两歧双歧杆菌TMC3115菌粉。
进一步地,按质量份数计,所述食品包括3-5份混合菌粉A,30-50份圆苞车前子壳,20-30份低聚果糖,4-10份菊粉,4-6份柳橙果粉;
所述混合菌粉A包括质量比为1:1的鼠李糖乳杆菌LR519菌粉与两歧双歧杆菌TMC3115菌粉。
本发明的工作原理及有益效果为:
1、本发明中通过对鼠李糖乳杆菌LR519菌粉与两歧双歧杆菌TMC3115菌粉的复配,提高了单一菌种对于绿脓杆菌和脱硫弧菌的抑制效果,抑制绿脓杆菌的抑菌圈直径在17.62-17.70mm,抑制脱硫弧菌的抑菌圈直径在20.95-21.04mm,用于改善便秘,连续服用14天,痊愈62.96%,有效33.33%,总有效率为96.30%,解决了现有技术中益生菌缓解便秘效果依旧不够好的问题。
2、本发明中不仅通过菌种的复配,结合辅料的设计,使得菌种得到有效的吸收。其中低聚果糖是一种天然活性物质,甜度是蔗糖的0.3-0.6倍,具有调节肠道菌群,增殖双歧杆菌、免疫调节等作用。低聚果糖在酸性条件下稳定性优于蔗糖,即使经过人体胃酸、胆汁的洗礼,也能够达到大肠中,为大肠中的双歧杆菌提供营养物质,使双歧杆菌迅速繁殖。此外,低聚果糖可抑制外源致病菌和肠内固有腐败细菌的生长繁殖、减少肠内腐败物质的积累,促进肠道蠕动和清洁,润肠通便,降低了有害毒素长时间滞留的现象,防止便秘或腹泻,改善消化系统的新陈代谢。
菊粉(天然果聚糖)和低聚果糖(FOS)有着亲缘关系。低聚果糖的糖链较短,而菊粉较长;因而菊粉的发酵速度更慢,产气速度也更慢。菊粉甜度是蔗糖的十分之一,不含卡路里,不会被人体自身消化,当它进入大肠后,它会被我们的肠道细菌利用。菊粉有着较好的选择性,它基本只会被“益菌”所利用,因而菊粉属于公认的益生元之一。菊粉还可以降低血糖,防便秘及治疗肥胖症膳食纤维减少食物在胃肠的停留时间,以及增加粪便量,有效地治疗便秘。适量摄入菊粉能帮助改善高血脂、缓解便秘以及帮助减肥。
柳橙果粉是以新鲜柳橙为原料,采用常温或低温喷雾干燥技术加工而成。柳橙果粉作为一种矫味剂,提供橘汁香味和甜度。柳橙甜美、略带酸味、口感清爽、富含维生素C。柳橙果粉均衡地含有水溶性纤维和非水溶性纤维,水溶性纤维具有降低血液中胆固醇指数及控制血糖水平的作用,而非水溶性纤维则能促进消化,帮助新陈代谢。维生素C可提高机体免疫力,有助于铁的吸收,协助肝脏内蛋白转氨、转硫等功能,将肠道吸收到肝脏的植物和动物蛋白氨基酸,转化成人体所需的各种酶、辅酶、神经递质、激素、谷胱甘肽等重要原料,保证身体更新修复代谢所需的营养原料。维生素C能促进胶原蛋白的正常合成,防止发生细胞连接障碍,缓解痔疮带来的痛苦。此外,维生素C又称l-抗坏血酸,是酸性的,而植物乳杆菌也最适宜在弱酸性(pH 6.5)环境下生存。维生素C是一种重要的自由基清除剂,它通过逐级供给电子而转变成半脱氢抗坏血酸和脱氢抗坏血酸,以达到清除氧自由基目的。维生素C与鼠李糖乳杆菌LR519协同起到清除体内自由基的作用。
圆苞车前子外壳富含胶质,由树胶醛醣、木糖、半乳胶醛酸、半干燥脂肪油及少量珊瑚木苷(Aucubine)组成。圆苞车前子壳中富含膳食纤维,高达80%以上,而其中可溶性膳食纤维与不溶性膳食纤维的比例高达7:3。其他营养成分主要包括葡萄糖甙、蛋白质、多糖、维生素B1和胆碱。圆苞车前子纤维可用于防止/治疗便秘或腹泻。它可充分吸收水分,增大体积至可排泄团块,增加肠道蠕动,减少粪便在肠内运送时间,并逐渐变得有规律。其可以帮助低聚果糖发挥对益生菌的定植作用。
3、本发明通过圆苞车前子外壳与低聚果糖的复配添加,进一步提高了鼠李糖乳杆菌LR519菌粉与两歧双歧杆菌TMC3115菌粉缓解便秘的作用。
附图说明
下面结合附图和具体实施方式对本发明作进一步详细的说明。
图1为本发明实施例1益生菌组合物抑制绿脓杆菌的效果图。
图2为本发明实施例1益生菌组合物抑制脱硫弧菌的效果图。
图3为本发明比较例1益生菌组合物抑制绿脓杆菌的效果图。
图4为本发明比较例1益生菌组合物抑制脱硫弧菌的效果图。
图5为本发明比较例2益生菌组合物抑制绿脓杆菌的效果图。
图6为本发明比较例2益生菌组合物抑制脱硫弧菌的效果图。
具体实施方式
下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。本发明涉及到的益生菌均由河北一然生物科技有限公司提供,其中鼠李糖乳杆菌LR519与两歧双歧杆菌TMC3115均已在专利公报中公开,公开的专利申请文件申请号为201911301091.1,申请日2019.12.17,发明名称为缓解便秘及痔疮的益生菌组合物,并且已经经过国家知识产权局承认的用于专利程序的保藏机构保藏,两歧双歧杆菌(Bifidobacteriumbifidum)TMC3115,保藏编号为CGMCC No.8462;鼠李糖乳杆菌(Lactobacillus rhamnosus)LR519,保藏编号为CGMCC No.15969;可以认定为公众可以得到、而不要求进行保藏的情形。
一、实施例
实施例1
一种能够缓解便秘的鼠李糖乳杆菌LR519组合物,所述组合物包括质量比为1:1的鼠李糖乳杆菌LR519菌粉与两歧双歧杆菌TMC3115菌粉。
实施例2
一种能够缓解便秘的鼠李糖乳杆菌LR519组合物,所述组合物包括质量比为1:2的鼠李糖乳杆菌LR519菌粉与两歧双歧杆菌TMC3115菌粉。
实施例3
一种能够缓解便秘的鼠李糖乳杆菌LR519组合物,所述组合物包括质量比为1:1.5的鼠李糖乳杆菌LR519菌粉与两歧双歧杆菌TMC3115菌粉。
比较例1
与实施例1相比,区别仅在于,未包括鼠李糖乳杆菌LR519菌粉。
比较例2
与实施例1相比,区别仅在于,未包括两歧双歧杆菌TMC3115菌粉。
比较例3
一种能够缓解便秘的鼠李糖乳杆菌LR519组合物,所述组合物包括质量比为10:1的鼠李糖乳杆菌LR519菌粉与两歧双歧杆菌TMC3115菌粉。
比较例4
一种能够缓解便秘的鼠李糖乳杆菌LR519组合物,所述组合物包括质量比为2:1的鼠李糖乳杆菌LR519菌粉与两歧双歧杆菌TMC3115菌粉。
脱硫弧菌、绿脓杆菌与便秘状态的发生高度相关,因此以实施例1-3及比较例1~3的益生菌为目标菌,进行如下目标菌体外抑菌实验:
脱硫弧菌活化三代后,用1×108CFU/mL浓度的脱硫弧菌涂布到新鲜的哥伦比亚血平板上,立即放入牛津杯,加入各待测目标菌100μL,微需氧条件下固定1h。培养72h后,测量抑菌环直径;绿脓杆菌活化三代后,用1×108CFU/mL浓度的绿脓杆菌涂布到新鲜的营养肉汁琼脂平板上,立即放入牛津杯,加入各待测目标菌100μL,微需氧条件下固定1h。培养72h后,测量抑菌环直径结果如下表1,效果图见图1-6。
表1
从上表中数据可以看出,目标菌体外抑菌实验加入的目标菌总量是相同的,实施例1-3采用鼠李糖乳杆菌LR519和两歧双歧杆菌TMC3115协同,抑制绿脓杆菌的抑菌圈直径在17.62-17.70mm,抑制脱硫弧菌的抑菌圈直径在20.95-21.04mm,比较例1-2单独采用鼠李糖乳杆菌LR519或两歧双歧杆菌TMC3115,相较于实施例1-3,比较例1-2抑菌圈的直径减小,可见本发明采用鼠李糖乳杆菌LR519和两歧双歧杆菌TMC3115复配协同提高了抑菌效果。
二、应用实施例
应用实施例1
按质量份数计,所述食品包括4份混合菌粉A,40份圆苞车前子壳,25份低聚果糖,8份菊粉,5份柳橙果粉;
所述混合菌粉A包括质量比为1:1的鼠李糖乳杆菌LR519菌粉与两歧双歧杆菌TMC3115菌粉。
应用实施例2
按质量份数计,所述食品包括3份混合菌粉A,50份圆苞车前子壳,20份低聚果糖,10份菊粉,4份柳橙果粉;
所述混合菌粉A包括质量比为1:2的鼠李糖乳杆菌LR519菌粉与两歧双歧杆菌TMC3115菌粉。
应用实施例3
按质量份数计,所述食品包括5份混合菌粉A,30份圆苞车前子壳,30份低聚果糖,4份菊粉,6份柳橙果粉;
所述混合菌粉A包括质量比为1:1.5的鼠李糖乳杆菌LR519菌粉与两歧双歧杆菌TMC3115菌粉。
对比应用实施例1
一种辅助缓解便秘及痔疮症状的益生菌组合物,其包括组分A:称取3.5份植物乳杆菌LP45菌粉、2份嗜酸乳杆菌La28菌粉、1份鼠李糖乳杆菌LR519菌粉和0.1份两歧双歧杆菌TMC3115菌粉混合均匀;组分B:称取41.2份乳糖醇,38份低聚果糖,9份菊粉,5份柳橙果粉,0.2份维生素C混合均匀。
对比应用实施例2
与应用实施例1相比,区别仅在于不包括圆苞车前子壳。
对比应用实施例3
与应用实施例1相比,区别仅在于不包括低聚果糖。
便秘人群试服
1、试服方法
选取符合入组条件的人群120人,分四组,四组受试者每天早饭前分别温水冲服应用实施例1、对比应用实施例1-3制备的产品,每次一袋,2g/袋,连续服用14天。试服期间要求受试者每天根据自身情况填写试服情况记录表。以患者自身试服前后症状作为对照,比较患者排便情况的改善程度。
2、入选标准:年龄18-60岁;符合便秘罗马III标准;病程最少半年;近一周内未服用影响胃肠道动力药物;诊断IBS依据不足;结肠镜或结肠造影检查排除肠道器质性病变及由全身性疾病引起的便秘;近三月满足以下两项或两项以上症状:①至少25%的排便感到费力②至少25%的排便为干球状便或硬便③至少25%的排便有不尽感④至少25%的排便有肛门直肠的阻塞感⑤排便次数每周少于3次。
3、排除标准:因其他疾病及药物导致的便秘,如帕金森氏综合症,巨结肠及长期服用止痛药患者;部分功能性便秘,如直肠前膨出,盆地痉挛综合症等;因嗜酒、滥用药物及精神因素依从性差者;长期滥用泻剂者。如观察期间出现患者自行使用胃肠道动力药(如开塞露),自行放弃观察等情况,则终止观察。
观察指标:比较患者治疗前后排便次数、排便指标、排便时间、粪便硬度、排便感觉。
表2评分标准
评分 | 排便次数 | 排便时间 | 粪便硬度 | 排便感觉 |
0 | 每日一到两次 | <5min | 很软 | 很轻松 |
1 | 每周四次 | <10min | 软 | 轻松 |
2 | 每周三次 | 10-15min | 一般 | 一般 |
3 | 每周两次 | 15-25min | 硬 | 费力 |
4 | 每周一次 | >25min | 很硬 | 很费力 |
4、试服结果
本次研究完成试服人数117人,应用实施例1的结果:除2人服用后症状没有得到有效改善外,其余25人均有效果。在试服两周后27名受试者中有17人的便秘症状完全消失,9人部分症状得到缓解,1人没有改善,即痊愈62.96%,有效33.33%,总有效率为96.30%。
以患者自身试服前后症状作为对照,根据患者排便情况进行量化打分。治疗前后四个排便症状包括粪便硬度、排便时间、频率、和排便感觉的量化积分值都有显著降低。说明本发明制备的复合益生菌粉可以显著改善患者便秘症状。
表3为治疗前后症状体征量化积分值变化表
注:P<0.05。
以上仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (5)
1.一种能够缓解便秘的鼠李糖乳杆菌LR519组合物,其特征在于,所述组合物由质量比为1:(1-2)的鼠李糖乳杆菌LR519菌粉与两歧双歧杆菌TMC3115菌粉组成。
2.根据权利要求1所述的一种能够缓解便秘的鼠李糖乳杆菌LR519组合物,其特征在于,所述组合物由质量比为1:1的鼠李糖乳杆菌LR519菌粉与两歧双歧杆菌TMC3115菌粉组成。
3.根据权利要求1或2所述的一种能够缓解便秘的鼠李糖乳杆菌LR519组合物的应用,其特征在于,用于制备缓解便秘的食品。
4.根据权利要求3所述的一种能够缓解便秘的鼠李糖乳杆菌LR519组合物的应用,其特征在于,按质量份数计,所述食品包括3-5份混合菌粉A,30-50份圆苞车前子壳,20-30份低聚果糖,4-10份菊粉,4-6份柳橙果粉;
所述混合菌粉A由质量比为1:(1-2)的鼠李糖乳杆菌LR519菌粉与两歧双歧杆菌TMC3115菌粉组成。
5.根据权利要求3所述的一种能够缓解便秘的鼠李糖乳杆菌LR519组合物的应用,其特征在于,按质量份数计,所述食品包括3-5份混合菌粉A,30-50份圆苞车前子壳,20-30份低聚果糖,4-10份菊粉,4-6份柳橙果粉;
所述混合菌粉A由质量比为1:1的鼠李糖乳杆菌LR519菌粉与两歧双歧杆菌TMC3115菌粉组成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011343439.6A CN112237287B (zh) | 2020-11-26 | 2020-11-26 | 一株能够缓解便秘的鼠李糖乳杆菌lr519及其组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011343439.6A CN112237287B (zh) | 2020-11-26 | 2020-11-26 | 一株能够缓解便秘的鼠李糖乳杆菌lr519及其组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112237287A CN112237287A (zh) | 2021-01-19 |
CN112237287B true CN112237287B (zh) | 2022-11-29 |
Family
ID=74175395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011343439.6A Active CN112237287B (zh) | 2020-11-26 | 2020-11-26 | 一株能够缓解便秘的鼠李糖乳杆菌lr519及其组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112237287B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116121136A (zh) * | 2022-12-30 | 2023-05-16 | 杭州康源食品科技有限公司 | 一种缓解便秘的益生菌组合物及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106954847A (zh) * | 2017-03-30 | 2017-07-18 | 广州能靓生物技术有限公司 | 具有润肠通便功能的酵素益生菌组合物、应用及加工制剂 |
CN109198356A (zh) * | 2018-11-23 | 2019-01-15 | 温友来 | 一种具有调节肠道功能的固体饮料及其制备方法 |
CN110692885A (zh) * | 2019-11-13 | 2020-01-17 | 上海英库商务咨询有限公司 | 一种用于缓解便秘的益生菌保健饮料 |
CN110946913A (zh) * | 2019-12-17 | 2020-04-03 | 河北一然生物科技有限公司 | 缓解便秘及痔疮的益生菌组合物 |
-
2020
- 2020-11-26 CN CN202011343439.6A patent/CN112237287B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106954847A (zh) * | 2017-03-30 | 2017-07-18 | 广州能靓生物技术有限公司 | 具有润肠通便功能的酵素益生菌组合物、应用及加工制剂 |
CN109198356A (zh) * | 2018-11-23 | 2019-01-15 | 温友来 | 一种具有调节肠道功能的固体饮料及其制备方法 |
CN110692885A (zh) * | 2019-11-13 | 2020-01-17 | 上海英库商务咨询有限公司 | 一种用于缓解便秘的益生菌保健饮料 |
CN110946913A (zh) * | 2019-12-17 | 2020-04-03 | 河北一然生物科技有限公司 | 缓解便秘及痔疮的益生菌组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN112237287A (zh) | 2021-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7101565B2 (en) | Probiotic/prebiotic composition and delivery method | |
JP4580542B2 (ja) | 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物 | |
CN106619743A (zh) | 一种具有降血糖作用的益生菌固体饮料及其制备方法 | |
CN109430666A (zh) | 一种益生菌冻干粉固体饮料 | |
CN110946913B (zh) | 缓解便秘及痔疮的益生菌组合物 | |
CN111972670A (zh) | 一种润肠通便的组合物、固体饮料及应用 | |
CN108477617A (zh) | 一种润肠通便的益生菌粉及其制备方法 | |
KR20050057259A (ko) | 프로바이오틱 박테리아 : 락토바실러스 퍼멘텀 | |
CN113826692A (zh) | 一种益生菌固体饮料及其制备方法 | |
CN111227261A (zh) | 一种益生元组合物及其应用 | |
CN111004733A (zh) | 一种具有缓解便秘功能的凝结芽孢杆菌复合微生态制剂 | |
CN115074274A (zh) | 含乳酸菌的组合物及其用途 | |
JP2007031345A (ja) | 腸内環境改善作用を有する食品組成物 | |
CN102861108B (zh) | 一种用于治疗便秘的药物组合物及其应用 | |
CN111557404A (zh) | 助消化益生菌固体饮料及其制备方法 | |
CN108283285A (zh) | 一种糖尿病的理疗保健食品 | |
CN114921363A (zh) | 一种抑制脂肪积累的复合益生菌及其应用 | |
CN110692885A (zh) | 一种用于缓解便秘的益生菌保健饮料 | |
CN108402371A (zh) | 一种适合中老年便秘人群服用的益生元组合物 | |
CN112617083A (zh) | 一种润肠通便降血糖的益生元固体饮料及其制备方法 | |
JP2816726B2 (ja) | 腸内環境改善用組成物 | |
KR20040027180A (ko) | 비만 또는 당뇨병의 예방 및 치료 효과를 갖는 유산균발효 유제품 및 그 제조방법 | |
JP4808715B2 (ja) | 更年期障害予防・改善剤および機能性飲食品 | |
KR101133208B1 (ko) | 식물성 유산균을 이용한 장개선과 변비개선효과를 나타내는 기능성 대두 발효조성물 제조방법 | |
CN115120646A (zh) | 一种平衡肠道菌群的益生菌组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 050800 No. 16, bangxiu East Road, North District, high tech Industrial Development Zone, Zhengding County, Zhengding District, China (Hebei) pilot Free Trade Zone, Shijiazhuang City, Hebei Province Applicant after: Hebei Yiran Biotechnology Co.,Ltd. Address before: 050899 No.16, bangxiu East Road, Zhengding high tech Development Zone, Shijiazhuang City, Hebei Province Applicant before: HEBEI INATURAL BIOTECHNOLOGY Co.,Ltd. |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |